Patients receiving compounded versions have no guarantee that the preparation they receive matches what was used in clinical trials or behaves consistently from one injection to the next
The prevalence of CAN among diabetes patients ranges from 20 to 60%
Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL
Additionally, compounded NAD+ solutions come with a beyond-use date (BUD) after which any remaining solution should be discarded
This review integrates current evidence on how brain peptides contribute to AD pathophysiology, summarizes recent progress in peptide-based therapeutic strategies and delivery platforms, and critically examines the remaining barriers to clinical translation, including bloodbrain barrier penetration, metabolic stability, off-target effects, and the need for biomarker-guided patient stratification
Weight reductions were significant at 6 months ( 2.1 kg